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pts) for 6 months. Rest forced expiratory volume (FEV~), vital capacity (VC), 
total lung capacity (TLC), carbon monoxide diffusing capacity (DLco), its alve. 
olaf-capillary membrane component (DM), pulmonary venous and trensmitral 
flow velocitlel~ (for monitoring changes in LV and.diastolic pressure, EDP). left 
ventrlcular end.dlastolic (EDD) and end,systolic (ESD) dimensions, stroke 
volume (SV), ejection fraction (EF), fiber shodenlng velocity (Vcl) were mea- 
sured at baseline, 3 end 8 months, pVO=, peak dead epees to tidal volume 
ratio (pVDNT). ventllefory equivalent for CO;z production (VENCO=), VO~ at 
anaerobic threshold (VO~at) wore also determined, 
Result=: Compared with 14 healty voluntssr~. FEV~, VC, DLco, DM were 
Impalrod In CHF and did not Improve with carvadllol, It slgnlfleantty reduced 
LVEDP, BOB, BeD, and Increased SV, El=, Vcf but failed to ameliorate pVO~, 
VO~at. oVDNT. VENCO~ Placebo was not effective, Data at 3 and 6 months 
Cor~lu~/on~: Lack of pulmonary function Improvement desphe excellent 
amelioration at left ventrlculer function, suggs~lS the development in CHF of 
an Irreversible or slow reversible organio lung dleoase, or a need for phsrma. 
¢oioglcl~l pr0pedlss that carvedliol does not ponose, Persistent pulmoneP/ 
dysfunction may prevent pVO~ Improvement, 
• t ,ong,tefm Survive! lEft, at of in Dilated Metoprolo!  
Cardlomloplthy 
A, DI Len~rd~, R, DO M~rla, A, Gave=el, D, Gmgorl, M, ParotlnL G, S;insgra, 
L, ~lvstom, F, Long,m, E Bomoblch. F, CamortnL Oep~rtmenf at 
Caedtoto~, ~e;  Iat~f~ dt Fisiologl~ C/mica CNR, Mil~no, linty 
8~Ckl~0Un~: Although meloproiol (M) Is olfactlvo In dilated el~rdiomyop~thy 
(IDC), ~ontfolled ata am lacking on long term survival We evaluated the 
a~ect of M on long.term survival in 58~ pts with IDC. prospectively enrolled 
in a mufflcentsr registry and followed up for 52 t 32 months, M, uptttrated to 
the ma~lmum lolerated dose, was added to conventional therapy in 175 of 
them1 
R~ults: Soven,yo~r survtvel (8t% vs 60%, p .~ 0,0001) and transplant, 
free survival (69% w 49%, p ,= 0,0004) were higher In the 175 M.treatod 
pts 1hen in the 411 on standard treatment, By multivariate anatysls. M was 
as#colored to a 5t% redqetion for all.cause modallty (95% CI ~21 to 69%, 
p ,~ 0,00~) and a 34% for mortality or lransplentation (95% CI 5 to . 53%, p 
- 0,01), NYHA class, LV end diastolic diameter and palmonary wedge pros, 
sure w~l~ likewise predictive. Seven-year survival (80% v 62%, p ® 0,0036) 
and transplant-free suwlvat (68% v 51%, p = 0,0053) wore also higher in 
127 M,tmated cases than in 12"/controls, appropriately matched for key 
prognostic variables. Mpts showed a 30% reduction in all.cause mortality 
(98% CI to 48%, p = 0,0147) and a 26% reduction in mortality or 
transplantation (95% CI 7% to 41%, ~ = 0,0009), 
Conch~io~,~: The addition el metoprelol tO standard therapy, including 
ACE-tnhibltors, was effective in the long.term, reducing both all cause mor- 
tality and trnnsplant~tion mpatients with IDC, 
~ Beta,Blocker Therapy In Patients With Clinical 
Evidence o! Heart Failure After Acute Myocardial 
Infarction 
C,S, Spatulas, A,S, Hall, S,G, Ball. Institute for Cardiovascular Research, 
Unimrsity or Leeds, IlK 
B,'~ckground: Clinical evidence of congestive heart failure (HF) after acute 
myocardia! infarction (MI) is considered by many to be a contralndlcation to 
p-adrenergtc blockade, Furthermore, there is uncertainty as to the value of 
these agents following routine use of aspirin, thrembolytlc and ACE,inhibiter 
therapy, We examine clinical outcomes associated with optional to-blockade 
in a post MI population with evidence of HI=, 
Methods: We retrospectively analyzed data from the AIRE study (ran- 
domized, placebo-controlled trial of ramipril in 2006 post MI patients with 
clinical evidence of HF), At baseline, 20% o! the patients were receiving a 
t~-blocker, Diuretic treatment at randomization defined a high risk group with 
poorer left ventricular function (LVF). To eliminate confounding, we sepa- 
rately analyzed patients according to diuretic use, adjusting for the presence 
of multiple clinical signs of HF and 15 other baseline clinical variables. Each 
was simultaneously entered in a multivariate Cox regression model. 
Results: t~-blocker therapy was a significant independent predictor of 
reduction in the risk of all-cause mortality (34%. CI 10% to 51%, p .-:. 0,008) 
and severe HF t43%, C118 to 60%, p = 0.002) for the entire study population, 
Similar findings occurred in high risk patients receiving diuretic (39%, C110% 
to 58%, p = 0.012; 42%, CI 11% to 62%, p = 0.013) but not in those not 
requiring diuretic use (19%, CI -38 to 53%, NS; 41%, CI - 17% to 70%, NS). 
Conclusion: Our data indicate that in the modem era/~-blocker therapy 
benefits patients with clinical evidence of HF post MI. 
• Evidence Against Heart Rate Reduction aa the 
Primary Mechanism of  Act ion of  Carvedllol  In 
Chronic  Heart Failure 
J.D. Sockner.Bornateln, MIA, Lakes, B, Wu. For the U.S, Carvedilol 
InveBflgMOPa: Columbia Unlverel~ College of Physicians & Surgeorw New 
York, USA 
Carvedilol (CV) reduaee morbidity and modallty and Improvn quality of life 
In patients with head failure (HF). A mochanletio reid of hoed rata reduction 
(AHR) has been postulated, We evaluated the relationships betwoen the 
/~HR by CV and Its Iong.tam~ clinical and leR vQntdcular eff~"ts. 
Patients enrolled In the US tflats who received ¢awedllOI for their dou- 
ble.blind therapy were evaluated (n = 690), Moat had NYHA Iblll e/mpfoml, 
and mean ej~tion fraction (EF) was 0.23. CV was started at 6,25 mg BID 
and tltrated to 25.-50 mg BID over 4-,6 w~kll. ,~HR was ~l~lBted from 
the difference botween heed rates pdor Io and altQf titration, Logls~ m- 
gmseion was podormed to determine If ,.~HR wee re la~ to 1) progree,ldon 
el HF, 2) global assessment by physician and I~tlent, 3) ANYHA ¢!au, 4) 
Asympfom stalus, and 5) AEF PotioNs w~m divided by the n~dian ~HR 
with coml~aon ot outcome variable, 
~HR t'~ormlated signifimantly but weakly with ANYHA and ~I~F (r ~. 0,08, 
p ,= 0,03 and r ~ 0,15, p ~ 0,003, respe4:tively), Patients with the greatest 
AHR did not have a different clintoai out,=oma, 
,~HR door nat correlate strongly with the long.term effects of CV. Nauro, 
hormonal antagonism tndebendent of chronofm4~iQ effects m~y be the poman/ 
me(~hanism of benefit, The degree at ~,HR should not be the drama! 1elliot 
when treating patients with earvediiol, 
Eff~t of Carvedllol on Symptom 8¢om in Heart 
. . . .  Failure 
EM, Oilbml, M,A, Lukes, S, Wu, M,B, Fowler, For the US Carve~lol Hem1 
~ilure Study Group: Univen~ty of Utah. Salt Lake Cilg, UT, USA 
Patients (pts) in the US Carvedilol (C) Head Failure (HF) Tt~ls Program 
randdmi~ed to placebo (P, n ,= 398] or C (n = 698) had HF oymptoms 
assessed by a quantitative score of fatigue and of dyspnea (met, walking 
on level ground and climbing stairs) by a scale ot 0 (none) to 3 (severe). 
PIe' well,being was rated by a scale of 0 (YeW good) to 3 (Pcof)- Malimum 
possible overall score was 0-21, 
Results: Table o! within and between group (P vs C) changes at endpoint: 
Analyzed by baseline sevedty (submaxtmal exercise intoleraoceL overall 
Score improved on C vs P by 1,3 (p ~ 0.01), 0,5, and 1,8 (p = 0,10) in pts 
with mild, moderate or severe impairment, respectively. 
Question BL AP BL AC ,'~P vs C 
Ovoratl 8 4 063 8 3 1 27 0 64" 
Dyspnea-rest 0 5 0 04 0 5 0 04 O 08"" 
Dyspnea,level I I  O15 1.1 0 .17  00~ 
Dyspnea,stairs 1.? -0 18 1.7 -0.24 006 
Fatigue-i~st 00 ,0,07 08  ,0.11 0.04 
Fatigue.level 1.1 ~ 0 02 1.1 - O. 18 O, 16" 
Fatigue.eta(re 1 6 -.0.09 1,7 - 0.27 0.181 
Pts well,being 1 S Q.17 1.5 026 009 t 
• p = 0,Of:" p = 0,08: t p = 0003: t p = 0.09 [eL = t~sellno], 
Conclusion: Analyzed using a quantitative heart failure symptom score, 
canmdilol lreatment was associated with significant improvements in over, 
all score, and in exertional fatigue, with evidence for benefit regardless of 
baseline severity. 
• Contrast ing Effects o f  Intravenous Dofeti l ide and 
Amlodarene on Cardiac Sympathetic Ol ive in 
Patients With Congest ive Heart Failure 
M,F. Rousseau, P.E. Massart, L. Galanti, S.A. Ahn. J. Etienne, 
H,G. Pouleur. University of Louvain. Brussels. Belgium 
In contrast o IV dofetilide (DOF, a pure IKr blocker), IV amiodamne (AMIO) 
lowers aortic presstlre and hence, could trigger bamreceptor eflex. To assess 
the implications of this sy'~temic effect of AMIO at the cardiac level, corenaw 
sinus (CS) ~,ow (thermodilution) and aortic and CS norepinephrine (NE) 
concentrations were measured in 30 pts with congestive heart failure (NYHA 
II-IIh LVEF: 19 i 8%). before and after a 30 min infusion of placebo (P; n = 
12). DOF (8/4g/kg; n = 12) or AMIO (5 mg/kg; n = 6). CS flow was little affected 
by infusions (Pc +3.6°/o; DOF: -4.0%; AMIO: +4.7%; all NS) and myocardial 
02 consumption decreased slightly with all drugs (Pc -1.0 mllmin; AMIO: 
-0.2: DOF: -1.6: all NS). AMIO alone significantly decreased dP/dt Max 
and mean aortic P (-9 mmHg *&) whereas only DOF prolonged single lead 
QT (+106 ms *& vs + 10 with AMIO and +9 with P). However, AMIO increased 
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both aofflc NE (medlan:318 tO 337 p~ml) and CS NE (median 368 to 542 
gg/ml') In all pta and doubled the tmnsoa~a© sptllovor ot NE (median -99 Io 
- 198 pg/ml "~ )whereas node, CS and transcar~nc NE were not stgnlfeantly 
modified during P (median ~llover 8B to - 128 pg/ml: NS) or DOF (median 
sl~llover 82 tO -69 pg/ml; NS) infusions, Thus, in contrast o DOF, IV AMIO 
• gnlflcaNly Increased Carcll~ I~q~tthatl¢ ddve whk:h could partially explain 
the smaller (:IT p~,.,~-,~al~on e~J the low inck~,~c¢,e of ~rsedes de p~n~s 
during IV AMIO admtntalxntion, Fudhet stud1(~ am ~ tO doKemlne 
~ ~ h ~  ¢0~ allo I !~  ~ ~ antlaffhy~ a¢~y O! IV 
amtedarone, "p ,~ 0,0~ v~ P; ~ p < 0.05 vS OOF 
~ F J . d y  Ef f lca~/and Complk:Mlon~ of  e f l~ l l ln l  
~mk~arone  for  Ah~l l  Flbdl lMlon in Adv~ncld  
He ld  Fanum 
M.S, W~nf~cl, MH. Dralm~f, WG. S~nson,  L.W. S~evanson_ grn~/~m 
~d ~ Holm4 8o~ MA. USA 
Backgmun~ The ~ o~ m~a~ng a~damne tAM) am not weO, ciefN~ 
for PI~ with aM~ ~ (AFt) and ~ ~ Mill.ira (HF), 
~ Re¢on~ were m~wmd kx 37 ~,,7,,-,g,~ IRI ~ AM 
~ lot AFib ~ HF tree, e° admiumn, ~ al lasl feAow-up i
de~rm~l  for all plI. HF was due 1o CAD (16.43%) al¢0h01 (3B%), valve 
± t, LVIEF 24 ± ~,  LA du~ensm 5.3 ± 08 O~t, medum AF~ doralk:m 12 
mos. PtS mceNed oral AM stadmg at 1-2 ± 0.2 ~m/day. 
Re~sU/~- AM was decreased Io <1~0 ml~ m 9 ptm (24%), d~e m 
b r a ~  in S (14%), m~Mm~ HF m :2 (5%), 8rid Ot upset m 2 (5%). 
~ led fo permanent pacm~uikm  7 pts and i~N~l~ng d~gemn in 
anofh~ 8 pts. Comem~ ~o sinus d~l~n rammed ~,~,~-,ao,m'y in 3 i~s 
and with ~ caedlevetskm in 26 (anm. 7 ± 2 gins folal AM), fo~ 78% 
m_ ~,.ce~_ __ Altei median foaow-uD 9.5 mos, 21 (57%) of aft pts were 
slgl out ot AF~b. Aftra clischarge, 3pts had ~ anol'nee had 
hypomym~n and ~ ~vm ~ and t showad ~¢~y.  
Conctus~o~- AM wire eke'Ideal cardiovemon hes I~  indmi =rod modm- 
ate latin success foe AFib and advanced HF. The malor eady mm'oidily is 
bradycaeclk~ requmng pacemake¢ Gr d~sconlmuabon fcBgovin tn 41% 0t pts. 
11°15"3a I m~ pa.em wn~ LenVentr~'-r aystmmmm 
Require Chronic Anlicoagulation? A Prospective 
Analym 
N.D. Shanna. RS. Gon~i. E.F. Pt.lt~n. W.D. Weaver. PA MCCu~o~cjh 
Car0k~vascutar/nk~ma~cs andAssoc/a~e D~ec/o£ Cemer ~or ~ 
E ~  DMs~on of Camrk~ascu/ar MeGc,-~. Henry Fo~ Hear/and 
Vascular lnslitut~ Henn/ Fon~ l.fea~ S)~tem. (~e Fo~ Piace, St~te 3~, 
Detro~ M148202. USA 
Bac~gm~m,3: The ~ AHCPR guiOelmes foe CHF dmease management 
do not recommend the routine use of throne anl¢oagulabon and c~e 1~e 
lack of ~ t~tals in II~s area. Howevsr. warfarin is osed mulme;y by 
many ~ wilh me geal of prevention of LV mraw~us fom~;mon and 
~ eml~at~n, we sel oui Io imestigate the risk ~ of Itmse 
patients with LV thmmbus idontified by echocan:liogrephy as pro1 ol a hearl 
transplantation evaluation. 
Me#~(/s. We ido~tified 28 cases with LV t h ~  in a 144 patient con- 
seeulhm sedes wilh Iongitudinel follew.up for a median of 25 monlha. Pabems 
with prosthetic valves or EF > 35% were exctuded. Using an unmatched case- 
controf design and muttivacate techniques. 35 clinical and echocardiogmphic 
variables were evalualed for their independent relationship to LV lhrombus 
tonv, ation and subsequent thmmboembolism. 
Resuh's: The mean age of cases (n = 28) and controls (n = 116) was 502 
± 11.0 vs. 54.2 ± 11,1 years, with 22 (78.6%) and 78 (67.2%) being male. p 
> 0.05. The mean EF was 17.5 ± 5.5 vs. 20.0 ± 6.9 respectively, p > 0.05. 
The groups were likewise similar with respect to baseline characteristics. 
medic.at=on use. and comorbidities. Multiple logistic regression revealed an 
ischemic etiology of the ca~diomyopathy. OR = 3.04. 95% CI 1.04-8.83. p = 
0.04 and LV chamber size (LVIDD mm unit increment above referent). OR = 
1.09. 95% CI 1.03-1.16. p = 0.004. to be independent predictors of LV throm- 
bus formation when controlling for w~,darin and ASA utilization. All thrombi 
appeared at LVIDD >60 mm with a consistent, graded relationship seen be- 
tween thrombi frequency and increasing chamber size. Peripheral embolism 
occurred in ,5 (17.9%) vs. 13 (11.2%) of cases and controls respectively, p = 
0.34. 
Conclusions: These data support a risk-adjusted approach for the deci- 
sion to use warfarin in CHF patients. Those patients with ischemic ardiom~ 
opathies and dilated LV chamber sizes (LVIDD >60 ram) appear to be at 
particulady high risk. Future randomized trials in this group are warranted. 
_OofQtllldo, II New C I I I=  m Ant~ln~Flllmk~ Din9 
mlauc l l  ttotp~hll Adml i |k~n i  tm Co . imPe l  
Heart FMhlm - l l eoml ry  Endpoh~tl e~ the 
DIAMOND~HF Study 
L. Kaber, The Oar~h/m, eee/~t~m #,4~,~ a n d ~  ON 
(Dt~MOND) ~ ll~<,,n< , ~./~, ot Ca~Lg~,  ~,meee Ummq,~v 
BaotgtOWld: Th~ DIAMONI)-CHF Iludy ¢lemonltllltod ~ ~ w~ 
~afe m pm~m~ w~ congt~N~ t.mrt fa~w~ (CH~, O~ ot 8 mm.m~ 
M~hod~' In th~ 01AMOND t~ 1518 P411~m~ to hot~M w~ 
CHF alXI wflh IIt~'~'~ left ~INft~laf syltoItc d ~  (will mott0~  
1 ~:, ~ - ~ . g  to ~ fmclkm below ~%) m m~mte ld  to 
a~a, ve dok~lk~ (03S-1 mg ¢la~y) 0, ~ m a ~ ~ ~ 
I~nm~al fe~ow up vra= ~ mor~,  EigM tmco~aW ~ were: i,,Iolliil 
~t~sKxl  w,h CHF req~nng ~-,ma~ m ~ne~ MCHF, m4olypes M 
~¢ammt. ~kyva=¢uta~  in ~ w~ atmd mmv~mo~, mveca~'~t 
mta~'lm~ e~,h an~ damng ct~u'~t~ otdo f~t~ (~ 300 lmtmm~). 
R~m~: Them were 228 hO~l~al ~ w~h wonleemg of CHF on 
dof~;~iu and 2g0 en p~cebo. The nsk mdu¢Imn was 0.TS ~h 95% ~ 
dent° ~m~its 0.63k-O,89. p ,< 0.001, Thls nlk indic!ran was sun in pslienls 
ea~ wem neuUl. 
worllenmg ol CHF. Th~ ~ ~ fo be i ~  i n d ~  of 1tin 
effect of the drog on atrial Ittm]la~on. 
Heml Fa.um 
T. TSul~IlOfo, K Maa¢~ N ~ ,  T. Htsanaga. A. Wada. D. Fukai, 
M. OhniM~. M. Smvaki. MasahA, o Kax=tl~l~ ,~ ~ of Medea/ 
Soe¢,~ Ofsg Japan 
Back~ Not only ~ t~t al~o immune ach-cat~on may nave an 
a~onant  rote m me pmgmmon ot cc<~ heart ~ture (OHF1. Chn~c 
effec~ ol angiolmmm It (ang II) type 1 receptor a n ~  on the mmcane 
system remains unknown. 
Mef/xx~¢ To ¢lalmm/ne 1he chronic effects ( 14 weeks) of ang II b/p° I 
anta0o,~st 0rCV-llS) on plasma k.mts of cy~kmes anO soluble 
a(~esmn ~ were e~aluated m n~ld to modera~ CHF palmnts In 
= 14, electron frachon (El:) <45%, NYHA class I1-t11] and compared w~l 
p~acebo (n = S) 
Resuns: 
NYH& class EF Ang II IL-6 TNF_  MC/EM- 1 sVCNdb 1
Pm-TCV 25  37 34 4 IS 54 324 865 
TCV 1 6" 41" S0" 25" 4.3" 2159" 669" 
(IL-6 = mtevletd~n 6. TNF= = tLZmO~ t~crosm faclor ~, sfCAM-I = soluble mMecellul~ 
a ~  ~ 1 .  sVCAM-1 = soh,4~e vasc-,Jlar aolles~n m0Mcuks-t "=p < 0.05 VS, 
pre-'rcv). 
Them ~ no ~ changes of ~ paramme~ and neurol~moral 
a~l ~ levis in ff~e placebo group. In ~ plasma levals of IL-6, 
TNF~e. stCAM-1, and sVCAM-1 were ~,~-d;'~-./deCtlrased co;i-.;;d~,~; with 
the increase m EF and wilh ~ m symptoms in the TCV group, 
Conc/tn~...~-  findings ~ IJlat the chrome treatment of ang 11 
I recapfor antegonisl mtprove the actwations of the m~Jne system in 
patients wtfll CHE 
